Crovalimab

DB16128ApprovedInvestigationalProtein Based TherapiesComplement C5 inhibitors

Crovalimab is a complement C5 inhibiting antibody used to treat paroxysmal nocturnal hemoglobinuria in adults and adolescents. It consists of two heavy chains (451 amino acid residues each) and two light chains (217 amino acid residues each).

Mechanism: Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder characterized by hemolysis and thrombosis. Symptoms and manifestations of PNH are developed by the activation of the classic complement pathway, leading to the formation of membrane attack complex (MAC) and intravascular hemolysis.
Crovalimab binds to the complement protein C5 β-chain with high affinity. C5-bound crovalimab is taken up by endothelial cells to be disposed of in endosomes; thus, crovalimab blocks the cleavage of C5 into C5a and C5b mediated by C5 convertase, preventing the formation of membrane attack complex (MAC). Crovalimab also inhibits C5b6 deposition on membranes to attenuate MAC-mediated tissue damage.
Curator reviewed · 8 references
Primary indication: Crovalimab is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg.Curator reviewed · 1 structured indication
Formula / weight: C₆₄₃₀H₉₉₇₄N₁₇₂₆O₂₀₂₆S₄₆ · 145000.0 Da (approximate)
First approval: Canada, 2025 · United States, 2024 · European Union, 2025
Also known as: Complement c5 inhibitory humanized recycling monoclonal antibody (rg-6107 ) · IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS C5 (COMPLEMENT 5)), MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN (1-451) (VH (VICUGNA PACOS IGHV3S1*01 (70.4%)/HOMO SAPIENS IGHV3-66*01 (69.4%)-(IGHD)-HOMO SAPIENS IGHJ4*01 (100%)) (9.8.15) (1-123)-HOMO SAPIENS IGHG1* · Immunoglobulin g1, anti-(human complement c5)(humanized ro7112689 heavy chain), disulfide with humanized ro7112689 light chain, dimer
Code names: RG-6107 · RO-7112689 · SKY-59
Brand names: Piasky